---
schema_version: "secwatch.filing_event.v1"
accession: "0000719135-24-000024"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:34:18.696138+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q1 revenue $10.2M (-16% YoY); net loss $7.6M; Chairman retires

## Summary
- Total revenue $10.2M (-16% YoY); Advanced Energy $7.5M (-23%); OEM $2.8M (+14%).
- Net loss $7.6M ($0.22/share) vs $3.5M ($0.10) loss a year ago; Adjusted EBITDA loss $5.3M vs $4.0M.
- Reaffirms FY2024 guidance: revenue $49.7M-$52.9M; net loss expected $24.3M-$26.5M.
- Chairman Andrew Makrides retires after 42 years; Stavros Vizirgianakis elected Chairman effective May 7, 2024.

## SEC filing metadata
- accession: 0000719135-24-000024
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000071913524000024/0000719135-24-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000071913524000024/apyx-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000719135-24-000024
- JSON: https://secwatch.observer/filing/0000719135-24-000024.json
- Plain text: https://secwatch.observer/filing/0000719135-24-000024.txt

## Key facts
- Earnings Releases
  Apyx Medical Corp reported first quarter ended March 31, 2024 results: revenue $10.2 million, net income $7.6 million, EPS $0.22 per share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $10.2 million
  - Net income: $7.6 million
  - EPS: $0.22 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024 First Quarter 2024 Financial Summary : • Total revenue of $10.2 million, a decrease of 16% year-over-year. ◦ Advanced Energy revenue of $7.5 million, a decrease of 23% year-over-year. ◦ OEM revenue of $2.8 million, an increase of 14% year-over-year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/719135/000071913524000024/0000719135-24-000024-index.htm
- Earnings Releases
  Apyx Medical Corp reported year ending December 31, 2024 results: revenue $49.7 million to $52.9 million. Guidance reaffirmed.
  - Period: year ending December 31, 2024
  - Revenue: $49.7 million to $52.9 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: respectively . Full Year 2024 Financial Outlook: The Company is reaffirming its financial guidance for the year ending December 31, 2024: • Total revenue in the range of $49.7 million to $52.9 million, representing a decrease of approximately 5% to growth of approximately 1% year-over-year, compared to total revenue of $52.3 million for the year ended December
  evidence_url: https://www.sec.gov/Archives/edgar/data/719135/000071913524000024/0000719135-24-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.